Physician profile
Margaret Donovan
NPI 1962955849
$1,834.23
in general payments reported to CMS, 2019-2025
22 companies · $514 in 2025
The $514 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $309 · 2024: $1,010 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.91 | 2024-2025 | |
| Novo Nordisk INC | $231.14 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Inspire Medical Systems, INC. | $195.58 | 2024-2025 | Inspire |
| Pfizer INC. | $178.47 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $134.35 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $111.92 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $83.85 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.50 | 2023-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $76.03 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $63.38 | 2024-2025 | |
| Amgen INC. | $61.08 | 2024-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $43.93 | 2024 | Apretude |
| Glaxosmithkline, LLC. | $42.32 | 2024 | Arexvy, Bexsero, Shingrix |
| Regeneron Healthcare Solutions, INC. | $31.90 | 2024 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $25.80 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.02 | 2024 | |
| Lundbeck LLC | $24.16 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $19.49 | 2025 | Recorlev |
| Biogen, INC. | $18.99 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $15.35 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $14.44 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $13.62 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.